New Biotech Syndeio Launches with $90M to Target Synaptic Plasticity in Neurological Disorders

Syndeio Biosciences, a new player in the pharmaceutical industry, has emerged with a substantial $90 million in initial funding to develop treatments for neurological disorders by modulating synaptic plasticity. The company, founded by alumni from Karuna Therapeutics and Naurex, aims to address major depressive disorder (MDD), Alzheimer's disease, and schizophrenia through its innovative approach to synapse-targeted therapies.

Founders and Funding

Syndeio's leadership team boasts an impressive roster of industry veterans and acclaimed scientists. Derek Small, former CEO of Naurex, leads the company as CEO. The founding team also includes Steve Brannan and Anantha Shekhar, both former executives at Karuna Therapeutics, and Nobel Laureate Thomas Südhof.

The $90 million Series A funding round was led by Catalio Capital Management and Innoviva, with strategic investments from pharmaceutical giants AbbVie and Eli Lilly. This substantial initial funding underscores the industry's confidence in Syndeio's approach and potential.

Scientific Approach and Pipeline

Syndeio's core focus is on optimizing synaptic function to treat various neurological disorders, collectively referred to as synaptopathies. The company's proprietary Boost synapse pharmacology platform combines molecular, functional, and behavioral models to predict treatment outcomes and develop effective dosing strategies for its synaptogenic agents.

The biotech's lead candidate, zelquistinel, is currently in Phase II clinical trials for major depressive disorder. Syndeio plans to initiate a first-of-its-kind synaptic function biomarker trial in Alzheimer's disease in the near future. The company is also exploring additional synapse-targeted programs to expand its pipeline.

Market Potential and Industry Impact

Syndeio's approach addresses significant unmet needs in the treatment of neurological disorders. For instance, at least 30% of people with MDD fail to respond to two or more antidepressants, highlighting the potential market for new, effective therapies.

Derek Small emphasized that Syndeio's goal is to establish itself as a long-term, synapse modulating-focused company rather than pursuing a quick exit through acquisition. This strategy mirrors the success of Karuna Therapeutics, which was recently acquired by Bristol Myers Squibb for $14 billion following the FDA approval of its schizophrenia drug, Cobenfy.

As Syndeio continues to develop its pipeline and advance clinical trials, the pharmaceutical industry will be watching closely to see if the company's innovative approach to synaptic plasticity can deliver breakthrough treatments for some of the most challenging neurological disorders.